Your browser doesn't support javascript.
loading
Virus-like particle displaying SARS-CoV-2 receptor binding domain elicits neutralizing antibodies and is protective in a challenge model
Julia L McKechnie; Brooke Fiala; Clancey Wolf; Daniel Ellis; Douglas Holtzman; Andrew Feldhaus.
Afiliação
  • Julia L McKechnie; Icosavax, Inc.
  • Brooke Fiala; Icosavax, Inc.
  • Clancey Wolf; Icosavax, Inc.
  • Daniel Ellis; Icosavax, Inc.
  • Douglas Holtzman; Icosavax, Inc.
  • Andrew Feldhaus; Icosavax, Inc.
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-518404
ABSTRACT
While the effort to vaccinate people against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has largely been successful, particularly in the developed world, the rise of new variants as well as waning immunity illustrate the need for a new generation of vaccines that provide broader and/or more durable protection against infection and severe disease. Here we describe the generation and characterization of IVX-411, a computationally designed, two-component virus-like particle (VLP) displaying the ancestral SARS-CoV-2 receptor binding domain (RBD) on its surface. Immunization of mice with IVX-411 generates neutralizing antibodies against the ancestral strain as well as three variants of concern. Neutralizing antibody titers elicited by IVX-411 are durable and significantly higher than those elicited by immunization with soluble RBD and spike antigens. Furthermore, immunization with IVX-411 is shown to be protective in a Syrian Golden hamster challenge model using two different strains of SARS-CoV-2. Overall, these studies demonstrate that IVX-411 is highly immunogenic and capable of eliciting broad, protective immunity.
Licença
cc_by
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...